These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25009956)

  • 1. Recent progress in HIV vaccines inducing mucosal immune responses.
    Pavot V; Rochereau N; Lawrence P; Girard MP; Genin C; Verrier B; Paul S
    AIDS; 2014 Jul; 28(12):1701-18. PubMed ID: 25009956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress towards an AIDS mucosal vaccine: an overview.
    Yuki Y; Nochi T; Kiyono H
    Tuberculosis (Edinb); 2007 Aug; 87 Suppl 1():S35-44. PubMed ID: 17652028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal HIV vaccines: a holy grail or a dud?
    Azizi A; Ghunaim H; Diaz-Mitoma F; Mestecky J
    Vaccine; 2010 May; 28(24):4015-26. PubMed ID: 20412879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.
    Belyakov IM; Ahlers JD
    Trends Immunol; 2008 Nov; 29(11):574-85. PubMed ID: 18838298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development.
    Belyakov IM; Ahlers JD
    Curr Top Microbiol Immunol; 2012; 354():157-79. PubMed ID: 21203884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innate gamma/delta T-cells during HIV infection: Terra relatively Incognita in novel vaccination strategies?
    Agrati C; D'Offizi G; Gougeon ML; Malkovsky M; Sacchi A; Casetti R; Bordoni V; Cimini E; Martini F
    AIDS Rev; 2011; 13(1):3-12. PubMed ID: 21412385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.
    Hinkula J
    Expert Rev Vaccines; 2007 Apr; 6(2):203-12. PubMed ID: 17408370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for optimizing targeting and delivery of mucosal HIV vaccines.
    Ahlers JD; Belyakov IM
    Eur J Immunol; 2009 Oct; 39(10):2657-69. PubMed ID: 19609978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS.
    Ahlers JD; Belyakov IM
    Trends Immunol; 2010 Mar; 31(3):120-30. PubMed ID: 20089450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal and systemic anti-GAG immunity induced by neonatal immunization with HIV LAMP/gag DNA vaccine in mice.
    Goldoni AL; Maciel M; Rigato PO; Piubelli O; de Brito CA; Melo A; Marques ET; August JT; Duarte AJ; Sato MN
    Immunobiology; 2011 Apr; 216(4):505-12. PubMed ID: 20870310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel approaches in polyepitope T-cell vaccine development against HIV-1.
    Karpenko LI; Bazhan SI; Antonets DV; Belyakov IM
    Expert Rev Vaccines; 2014 Jan; 13(1):155-73. PubMed ID: 24308576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immune responses to the human immunodeficiency virus type-1 (HIV-1) in the genital tract compared to other mucosal sites.
    Mestecky J
    J Reprod Immunol; 2006 Dec; 72(1-2):1-17. PubMed ID: 17095369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immunodeficiency virus antibodies and the vaccine problem.
    Chiodi F; Weiss RA
    J Intern Med; 2014 May; 275(5):444-55. PubMed ID: 24581142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy.
    Jackson RJ; Worley M; Trivedi S; Ranasinghe C
    Vaccine; 2014 Sep; 32(43):5703-14. PubMed ID: 25151041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.
    Bråve A; Hallengärd D; Schröder U; Blomberg P; Wahren B; Hinkula J
    Vaccine; 2008 Sep; 26(40):5075-8. PubMed ID: 18450334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal AIDS vaccines.
    Bourinbaiar AS; Metadilogkul O; Jirathitikal V
    Viral Immunol; 2003; 16(4):427-45. PubMed ID: 14733732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery systems and adjuvants for vaccination against HIV.
    Velin D; Kraehenbuhl JP
    EXS; 2000; 89():227-37. PubMed ID: 10997292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Maginot Line and AIDS vaccines.
    Stricker RB; Goldberg B
    Med Hypotheses; 1997 Jun; 48(6):527-9. PubMed ID: 9247898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in mucosal HIV vaccine development: lessons from non-human primate models.
    Tuero I; Robert-Guroff M
    Viruses; 2014 Aug; 6(8):3129-58. PubMed ID: 25196380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines.
    Belyakov IM; Berzofsky JA
    Immunity; 2004 Mar; 20(3):247-53. PubMed ID: 15030769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.